Literature DB >> 4132893

Use of plasma levels in evaluation of procainamide dosage.

T R Shaw, C R Kumana, R B Royds, C M Padgham, J Hamer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4132893      PMCID： PMC458828          DOI： 10.1136/hrt.36.3.265

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


× No keyword cloud information.
  6 in total

1.  Arrhythmias and late sudden death after myocardial infarction.

Authors:  M A Denborough; R R Lovell; P J Nestel; A J Goble
Journal:  Lancet       Date:  1968-02-24       Impact factor: 79.321

2.  Long-term use of procaine amide following acute myocardial infarction.

Authors:  B D Kosowsky; J Taylor; B Lown; R F Ritchie
Journal:  Circulation       Date:  1973-06       Impact factor: 29.690

3.  Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.

Authors:  J Koch-Weser; S W Klein; L L Foo-Canto; J A Kastor; R W DeSanctis
Journal:  N Engl J Med       Date:  1969-12-04       Impact factor: 91.245

4.  Drug therapy. Serum drug concentrations as therapeutic guides.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1972-08-03       Impact factor: 91.245

5.  Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure.

Authors:  E G Giardina; R H Heissenbuttel; J T Bigger
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391

6.  Hospital mortality in acute myocardial infarction.

Authors:  R M Norris; K E Bensley; D E Caughey; P J Scott
Journal:  Br Med J       Date:  1968-07-20
  6 in total
  7 in total

1.  Acetylator phenotype and the clinical pharmacology of slow-release procainamide.

Authors:  W Campbell; W J Tilstone; D H Lawson; I Hutton; T D Lawrie
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

2.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

3.  Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.

Authors:  C R Kumana; V S Rambihar; K Willis; R N Gupta; P H Tanser; J A Cairns; R A Wildeman; M Johnston; A L Johnson; M Gent
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

4.  Procainamide absorption studies to test the feasibility of using a sustained-release preparation.

Authors:  T R Shaw; C R Kumana; C M Kaye; C Padgham; T Kaspi; J Hamer
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

5.  Adverse reactions to procainamide.

Authors:  D H Lawson; H Jick
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

6.  A pharmacokinetic comparison of two sustained-release oral procainamide preparations.

Authors:  P Hore; P Bones; T Rollinson; H Ikram
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

7.  A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.

Authors:  C R Kumana; V S Rambihar; P H Tanser; J A Cairns; R N Gupta; R A Wildeman; M Johnston; A L Johnson; M Gent
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.